A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s. (5th May 2020)

• Record Type: Journal Article
• Authors: Guaraldi, Federica; Zoli, Matteo; Righi, Alberto; Gibertoni, Dino; Marino Picciola, Valentino; Faustini‐Fustini, Marco; Morandi, Luca; Bacci, Antonella; Pasquini, Ernesto; Mazzatenta, Diego; Asioli, Sofia
• Is Part Of: Clinical endocrinology. Volume 93:Number 1(2020)
• Page Start: 36
• Page End: 43
• Publication Date: 2020-05-05
• Subjects: classification tree analysis -- outcome -- pituitary adenoma -- pituitary tumour -- progression; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.14197
• Languages: English
• ISSNs: 0300-0664

Abstract

Abstract: Objective: Pituitary neuroendocrine tumours (PitNET)s can be aggressive, thus presenting local invasion, postsurgical recurrence and/or resistance to treatment, responsible for significant morbidity. The study aimed at identifying prognostic factors of postsurgical outcome using data‐driven classification of patients. Design: Retrospective observational study. Methods: Clinicopathological and radiological data of patients with PitNET treated via endoscopic endonasal surgery were collected. Tumour recurrence/progression and progression‐free survival were assessed by classification tree analysis (CTA) and Kaplan‐Meier curves, respectively. Histological subtype, cavernous/sphenoid sinus invasion, mitosis, Ki‐67, p53, Trouillas' grading, degree of tumour exeresis and postsurgery disease activity were also evaluated. Results: A total of 1066 (466 gonadotroph, 287 somatotroph, 148 lactotroph, 157 corticotroph and 8 thyrotroph ) tumours were included; 21.7% invaded the cavernous/sphenoid sinus. Based on Trouillas' classification, 64.3% were grade 1a, 14.2% 1b, 16.1% 2a, and 5.4% 2b; 18.3% had >2/10 HPF mitoses, 24.9% had Ki‐67 ≥3%; 15.8% were positive for p53. Exeresis was radical in 81.2% of the cases. Median follow‐up was 59.2 months. At last evaluation, 79.4% of the patients were cured; 20.6% had disease persistence, controlled by medical treatment in 18.3% of them. Disease recurrence/progression was recorded in 10.9% of the cases. CTA identified 5 distinct patient subgroups with different risk of disease recurrence/progression. Grade 2 of the Trouillas' grading, >2/10 HPF mitoses, Ki‐67 ≥3%, p53 protein expression ( P < .001), tumour invasion ( P = .002) and ACTH‐subtype ( P = .003) were identified as risk factors of disease recurrence/progression. Conclusions: The combined evaluation of Trouillas' grading, proliferation indexes and immunohistochemistry appears promising in the prediction of surgical outcome in PitNET .